GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosyntech Inc (OTCPK:BSYI) » Definitions » Cash-to-Debt

Biosyntech (Biosyntech) Cash-to-Debt : 0.08 (As of Dec. 2009)


View and export this data going back to 2000. Start your Free Trial

What is Biosyntech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biosyntech's cash to debt ratio for the quarter that ended in Dec. 2009 was 0.08.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biosyntech couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2009.

The historical rank and industry rank for Biosyntech's Cash-to-Debt or its related term are showing as below:

BSYI's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.5
* Ranked among companies with meaningful Cash-to-Debt only.

Biosyntech Cash-to-Debt Historical Data

The historical data trend for Biosyntech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biosyntech Cash-to-Debt Chart

Biosyntech Annual Data
Trend Mar00 Mar01 Mar02 Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 4.53 3.07 1.16 0.41

Biosyntech Quarterly Data
Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.41 0.13 0.05 0.08

Competitive Comparison of Biosyntech's Cash-to-Debt

For the Biotechnology subindustry, Biosyntech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyntech's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosyntech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biosyntech's Cash-to-Debt falls into.



Biosyntech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biosyntech's Cash to Debt Ratio for the fiscal year that ended in Mar. 2009 is calculated as:

Biosyntech's Cash to Debt Ratio for the quarter that ended in Dec. 2009 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyntech  (OTCPK:BSYI) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Biosyntech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biosyntech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyntech (Biosyntech) Business Description

Traded in Other Exchanges
N/A
Address
475 Boulevard Armand-Frappier, Laval, QC, CAN, H7V 4B3
Biosyntech Inc is engaged in developing advanced biotherapeutics thermogels specifically designed for tissue repair and delivery of therapeutic agents. The company's products include BST-CarGel, BST-InPod, BST-DermOn, BST-Ossifil and BST-Ossifix and BST-Disc for intervertebral disc restoration.

Biosyntech (Biosyntech) Headlines

No Headlines